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Cytomegalovirus (CMV) reactivates in >30% of CMV-seropositive patients after allogeneic hematopoietic cell
transplantation (HCT). Previously, we reported an increase of natural killer (NK) cells expressing NKG2C,
CD57, and inhibitory killer cell immunoglobulinelike receptors (KIRs) in response to CMV reactivation after
HCT. These NK cells persist after the resolution of infection and display “adaptive” or memory properties.
Despite these ﬁndings, the differential impact of persistent/inactive versus reactivated CMV on NK versus T
cell maturation after HCT from different graft sources has not been deﬁned. We compared the phenotype of
NK and T cells from 292 recipients of allogeneic sibling (n ¼ 118) or umbilical cord blood (UCB; n ¼ 174) grafts
based on recipient pretransplantation CMV serostatus and post-HCT CMV reactivation. This cohort was uti-
lized to evaluate CMV-dependent increases in KIR-expressing NK cells exhibiting an adaptive phenotype
(NKG2CþCD57þ). Compared with CMV-seronegative recipients, those who reactivated CMV had the highest
adaptive cell frequencies, whereas intermediate frequencies were observed in CMV-seropositive recipients
harboring persistent/nonreplicating CMV. The same effect was observed in T cells and CD56þ T cells. These
adaptive lymphocyte subsets were increased in CMV-seropositive recipients of sibling but not UCB grafts and
were correlated with lower rates of CMV reactivation (sibling 33% versus UCB 51%; P < .01). These data
suggest that persistent/nonreplicating recipient CMV induces rapid production of adaptive NK and T cells
from mature cells from sibling but not UCB grafts. These adaptive lymphocytes are associated with protection
from CMV reactivation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTIONdgments on page 1661.
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ty for Blood and Marrow Transplantation.Natural killer (NK) cells are an important component of
the innate immune response against both tumors and virally
infected cells. NK cells mediate an antiviral response through
the direct killing of infected cells and through secretion of
cytokines and chemokines (eg, IFN-g, TNF, MIP-1b) that re-
cruit or modulate the adaptive immune response. NK cell
function is not triggered directly through recognition of
Z.B. Davis et al. / Biol Blood Marrow Transplant 21 (2015) 1653e16621654pathogen-associated antigens. Instead, the NK cell response
is regulated by various inhibitory NK cell receptors (iNKR)
and activating NK cell receptors (aNKR) that recognize li-
gands on target cells [1-3]. The best deﬁned iNKRs are the
killer cell immunoglobulinelike receptors (KIRs) that
recognize polymorphic epitopes on histocompatibility
leukocyte antigen (HLA) molecules (mainly, HLA-B and -C)
and the C-type lectin heterodimer, NKG2A/CD94, that rec-
ognizes the nonclassical HLA molecule, HLA-E. When trig-
gered by self-HLA, iNKRs induce an inhibitory signal cascade
that prevents NK cell activation. Inhibitory signals can be
overridden by aNKRs (eg, NKG2D, NKG2C), also expressed on
NK cells. The net balance between inhibitory and activating
signals determines whether NK cells kill transformed or
virally infected targets [2]. In the presence of targets with
surface expression of aNKR ligands and down-modulation of
self-HLA, the balance of signaling in NK cells is skewed to-
wards activation.
Human cytomegalovirus (CMV) is a common b-herpes-
virus that infects more than 60% of the US population [4]. In
healthy immunocompetent individuals, the immune
response quickly suppresses CMV replication, resulting in
asymptomatic or mild illness [5], leaving residual persistent
CMV where only a few CMV genes are undergoing tran-
scription [6]. Although healthy individuals rarely reactivate
CMV causing symptomatic infection, viral reactivation that
can occur during immunosuppression can lead to severe,
life-threatening complications [7,8]. Upon primary infection,
viremia results in activation of the innate and adaptive arms
of the immune system, leading to control of the virus. This
culminates in a polyclonal T cell response to viral epitopes
displayed in the context of HLA class I and II [9-11] as well as
neutralizing antibodies [12]. Interestingly, some studies have
demonstrated that responding T cells can acquire properties
of NK cells, including the expression of CD56 and associated
cytotoxicity and cytokine production [13]. Others have
shown that CMV-reactive T cell clones can also mediate
anticancer activity [14], suggesting a profound and poten-
tially unique impact of CMV on the adaptive immune system.
An increase of the CD56þ T cell subset has been observed in
elderly CMV-seropositive (Seroþ) individuals [15] and in
healthy CMV Seroþ individuals whose NK cells express high
levels of NKG2C and CD57 and produce IFN-g and TNFa after
exposure to CMV antigens [13].
Recently, a subset of murine NK cells was identiﬁed that
expanded after productive murine CMV (MCMV) infection.
This subset expresses the aNKR Ly49H and expands after
interaction between Ly49H and the MCMV-encoded protein
m157 [16]. Upon rechallenge with MCMV, this NK subset
exhibits a memory-like recall response. A similar increase of
NKG2C-expressing NK cells expands in humans after cocul-
ture with CMV-infected ﬁbroblasts and is highly enriched in
CMV Seroþ individuals [17,18]. NK cells expressing NKG2C
along with CD57 (NKG2CþCD57þ) are considered to be
“adaptive,” exhibiting memory-like responses with speciﬁc
function against CMV-infected cells. This population is also
increased in patients infected with hantavirus [19] and hu-
man immunodeﬁciency virus [20], but only in those who are
coinfected with CMV. In CMV-seronegative (Sero) patients
with other viral infections, the frequency of this NK popu-
lation is low [17]. NKG2C is an aNKR that recognizes HLA-E
but with a lower afﬁnity than the iNKR NKG2A [21]. It is
not known whether the increase of NKG2C-expressing cells
is mediated though interaction with HLA-E, viral peptide
loaded HLA-E, or an unknown ligand of viral or host origin.In this study, we evaluatedwhether the source of the graft
used for hematopoietic cell transplantation (HCT) affects
CMV-induced cellular immune responses. We hypothesized
that adaptive NK and T lymphocyte populations would be
enhanced after allogeneic sibling grafts from adult donors
compared with those from UCB grafts, which are of fetal
origin. We believe that mature CMV-speciﬁc lymphocytes
reconstituting from sibling donor grafts have the potential to
recognize recipient CMV, whereas UCB grafts have few, if any,
mature NK and T cells. We compared the reconstitution ki-
netics of CD56þCD3 NK cells, CD56þCD3þ T cells, and
CD56CD3þ T cells in CMV Sero or Seroþ recipients strati-
ﬁed on post-HCT CMV reactivation (Reactþ) versus non-
reactivation (React) to evaluate the impact of CMV infection
in shaping this adaptive immune response.
MATERIALS AND METHODS
Patients and Samples
Our cohort included 292 HCT recipients of allogeneic sibling (n¼ 118) or
UCB (n ¼ 174) grafts. These recipients were approximately one-half CMV
Sero (n¼ 140) and one-half CMV Seroþ (n¼ 152), of whom 83 were React
and 69 were Reactþ. Peripheral blood mononuclear cells were collected,
stained, and analyzed fresh from recipients after HCTat days 28, 60,100,180,
and 365. Patients were monitored weekly for CMV reactivation by a quan-
titative polymerase chain reaction (PCR) assay for viral DNA. A second cohort
of 394 HCT-Seroþ recipients of UCB (n ¼ 270) or allogeneic sibling (n ¼ 124)
from Sero donors (n ¼ 61) or Seroþ donors (n ¼ 63) was used to evaluate
CMV reactivation after transplantation. CMV reactivation was deﬁned as
viremia with >100 viral DNA copies per mL of blood from the University of
Minnesota Medical Center clinical virology laboratory. Samples from pa-
tients who underwent transplantation were acquired after obtaining
informed consent and approval from the University of Minnesota institu-
tional review board and in accordance with the declaration of Helsinki.
Staining, Acquisition, and Analysis
The ﬂuorochrome-conjugated antibodies used to assess phenotypes
were PE-Texas Red-conjugated anti-CD3 (clone S4.1, Life Technologies,
Carlsbad, CA), PE-Cy7-conjugated anti-CD56 (clone NCAM16.2, BD
Pharmingen, San Jose, CA), FITC-conjugated anti-CD158b (clone CH-L, BD
Pharmingen, San Diego, CA), FITC-conjugated anti-CD158a (clone HP-3E4,
BD Pharmingen), FITC-conjugated or PE-conjugated anti-NKB1 (clone DX9,
BD Biosciences), APC-conjugated anti-NKG2A (clone 13144, R&D Systems,
Minneapolis, MN), PE-conjugated anti-NKG2C (clone 134591, R&D Systems)
and Paciﬁc Blue-conjugated anti-CD57 (clone HCD57, Biolegend, San Diego,
CA). Data was collected using an LSRII ﬂow cytometer (BD Biosciences) and
analysis was performed using FlowJo 9.3.2 software (Treestar, Ashland, OR).
Statistical Analysis
The percentages of NK cells for different patient groups at different time
points were presented with mean  standard error of the mean. For
comparisons between groups with different pre-HCT CMV serostatus or
post-HCT CMV reactivation, t-test with equal or unequal variance (as
appropriate) was used. The cumulative incidences of CMV reactivation up to
100 days after HCT were estimated for the allogeneic sibling and UCB HCT
groups. Fine and Gray regression was employed to assess the independent
effect of donor type treating nonreactivation mortality as a competing risk.
Other factors considered in the regression models were diagnosis, year of
transplantation, conditioning, graft-versus-host disease (GVHD) prophy-
laxis, gender, disease risk, acute GVHD, age, and prior autologous trans-
plantation. Adjusted cumulative incidence curves were used to estimate
CMV reactivation, adjusting for risk factors from the Fine and Gray regres-
sion model. All tests were 2-sided. Statistical analyses were performed with
SAS 9.3 (SAS Institute, Cary, NC) and the R package cmprsk.
RESULTS
Seroþ Recipients and Reactþ Reconstitute with Increased
Frequencies of NK and T Cells Bearing an Adaptive
Phenotype in the First Year after HCT
To monitor immune reconstitution in HCT recipients,
peripheral blood was drawn from 292 patients receiving
sibling (n ¼ 118) or UCB (n ¼ 174) grafts at various time
points after HCT and evaluated for maturation and known
functional subsets of NK cells [22,23]. Patients were stratiﬁed
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reactivation after transplantation to identify the impact of
these 2 factors on immune reconstitution. We compared 3
groups; CMV Sero/React, CMV Seroþ/React with persis-
tent/nonreplicating CMV, and CMV Reactþ as determined by
weekly clinical PCR for CMV DNA.
We ﬁrst measured expression of NKG2C and CD57 as
markers for CMV-induced adaptive cells. When compared toFigure 1. Recipient CMV Seroþ/React and Reactþ results in expansion of KIR2DL2/3þ
evaluated from Sero/React (black bars, n ¼ 91), Seroþ/React (light gray bars, n ¼
KIR2DL1þ, (E) KIR2DL2/3þ, and (F) KIR3DL1þ expression was evaluated on CD56þCD3
Seroþ/React (light gray bars, n ¼ 54), and CMV Reactþ (white bars, n ¼ 57). Recipient
Bars represent the mean percentage of lymphocytes expressing each phenotype  SEM
was used for the pairwise comparisons between groups at each time point. *P < .05,CMV Sero/React, we measured increased expression of
NKG2C (including the NKG2CþCD57 subset) on NK cells
from Seroþ/React throughout the ﬁrst year after HCT. The
largest increases were found in the subset of Seroþ recipients
who reactivated CMV (Reactþ) (Figure 1A,B). Increased
NKG2CþCD57þ NK cells were found in Seroþ versus Sero
recipients at all time points evaluated, but the difference was
most prominent at 6 months (Figure 1B). Consistent with theand NKG2CþCD57þ NK cells after transplantation. (A) NKG2CþCD57þ cells were
53) and CMV Reactþ (white bars, n ¼ 59), (B) NKG2CþCD57, (C) NKG2Aþ, (D)
 NK cells after transplantation from CMV Sero/React (black bars, n ¼ 116),
samples were analyzed at 100 days, 6 months, and 1 year after transplantation.
. T test (equal variance or unequal variance t-test, based on variance test result)
**P < .01, ***P < .001.
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NKG2A expressionwas observed in Seroþ recipients, with the
most notable difference at 1 year after HCT (56%  4.2%
[Seroþ/React] versus 73%  1.3% [Sero/React]; P ¼ .0004).
A similar decrease was observed in Seroþ recipients who
reactivated (Reactþ) (Figure 1C).
We also evaluated KIR expression as a marker of NK
maturation and enhanced function [24]. Although the per-
centage of NK cells expressing the HLA-C2 speciﬁc KIR2DL1
(CD158a) was not different in each group (Figure 1D), the
Seroþ recipients did have a signiﬁcantly increased frequency
of NK cells that recognize HLA-C1 (expressing KIR2DL2/3
stained with CD158 b) (29%  2.5% [Seroþ/React] versus
22%  1.0% [Sero/React]; P ¼ .02) (Figure 1E). The differ-
ence was more pronounced when comparing the subset
from CMV Reactþ with Sero recipients. No signiﬁcant dif-
ferences were observed in expression of KIR3DL1 (stained by
CD158e), which recognizes HLA-Bw4 (Figure 1F).
Persistent, nonreactivated CMV and CMV reactivation
were associated with similar changes to the phenotype of
NKG2Cþ T cell subsets (Supplemental Figure 1). Signiﬁcant
increases in the percentage of NKG2CþCD57þ CD56þCD3þ T
cells were found in Seroþ recipients, especially in Reactþ
(15%  2.5%) versus Sero/React (2.1%  .5%) (P < .0001) for
up to 1 year (Figure 2A). Similarly, NKG2CþCD57
CD56þCD3þ T cells were increased (7.3%  1.2% [Reactþ]
versus 1.6%  .2% [Sero/React]; P < .0001) (Figure 2B). The
same NKG2CþCD57þ subset was increased in CD56CD3þ T
cells (.7% .2% [Reactþ] versus .1% .02% [Sero/React]; P¼
.0003) (Figure 3A) as was the NKG2CþCD57 subset (.6%  .2
[Reactþ] versus .1%  .02 [Sero/Seroþ]; P ¼ .0345)
(Figure 3B) throughout the ﬁrst year. CMV reactivation was
also associated with a concurrent decrease in NKG2A
expression on CD56þCD3þ T cells (Figure 2C); however, no
signiﬁcant decreases were observed in NKG2A expression on
CD56CD3þ T cells (Figure 3C). In contrast to NK cells, where
persistent/nonreplicating or reactivated CMV in recipients
was not associated with increases in KIR2DL1þ,
CD56þCD3þand CD56CD3þ T cells from the Reactþ groups
expressed signiﬁcantly more KIR2DL1þ from day 100 and
persisting to 1 year compared with Sero recipients
(Figures 2D, 3D). Corresponding increases in KIR2DL2/3-
expressing CD56þCD3þ and CD56CD3þ T cells were
observed over the ﬁrst year after HCT in Reactþ versus Sero
recipients (Figures 2E, 3E). Interestingly, CMV was not asso-
ciatedwith changes in the expression of KIR3DL1 on NK cells,
whereas both CD56þCD3þ and CD56CD3þ T cells exhibited
increased expression of this inhibitory receptor after
CMV reactivation, but not in Seroþ React recipients
(Figures 2F, 3F).
It should be noted that the NK cell and T cell increases
with CMV reactivation were similar in recipients of sibling
and UCB grafts (data not shown), whereas the increases to
nonreactivated persistent CMV in the Seroþ React recipients
differed based on graft type. Although no increases were
observed in seropositive recipients of UCB grafts, the in-
creases in adaptive cells were speciﬁc to the CMV Seroþ re-
cipients who received sibling grafts. Thus CMV, persistent or
nonreplicating in Seroþ recipients or replicating in recipients
who reactivate, imparts a global impact on reconstituting NK
cells and T cells after HCT. Increased frequencies of cells
primed for adaptive function are marked by NKG2C, and this
imprint is not exclusive to CD57þ cells. In most cases, the
data demonstrate a stepwise increase in the frequency of the
CMV adaptive lymphocyte subsets with signiﬁcant, butsmaller adaptive responses in persistent CMV-seropositive
recipients and the largest effect in recipients who reac-
tivate CMV. These ﬁndings suggest a dose response to CMV
exposure in mediating these cellular responses.
Persistent Recipient CMV Drives the Increase of Adaptive
NK and T Cell Subsets in Sibling but not UCB Graft
Recipients
To further evaluate the impact of persistent CMV infection
on NK and T cell reconstitution after HCT, we compared CMV
Sero/React and Seroþ/React, stratifying further on the
graft source (sibling versus UCB). After allogeneic sibling
transplantation, Seroþ/React recipients, who express
persistent/nonreplicating CMV, exhibited an increase in CMV
adaptive KIRþ (KIR2DL2þ/3þ) NK cells (32%  3.9%) by
6 months after HCT compared with Sero/React recipients
(21%  1.3%; P ¼ .01) (Figure 4A). Similarly, decreased
expression of NKG2A was measured on Seroþ versus Sero
recipients beginning 60 days after HCT and continuing to the
6-month time point (57%  4.1 [Seroþ/React] versus
77%  1.6 [Sero/React]; P ¼ .0002) (Figure 4B). This was
also associated with increased NKG2Cþ NK cells with
(Figure 4C) or without (Figure 4D) CD57 for up to 6 months
(12%  2.7% [Seroþ/React] versus 6%  .7% [Sero/React];
P¼ .05; and 10% 2.3% [Seroþ/React] versus 3% .6 [Sero/
React]; P ¼ .0095, respectively). Importantly, the effect of
persistent/nonreplicating recipient CMV expression on NK
and T cell reconstitution was not seen in recipients of UCB
grafts (Figures 4E-4H). Unlike UCB grafts, which are CMV
naïve, sibling donors are often exposed to CMV (39% in our
cohort) and produce grafts which may contain lymphocytes
which immunologically recognize CMV. Thus, the differential
response of CMV Seroþ recipients to grafts from sibling
versus UCB grafts may reﬂect the inﬂuence of donor expo-
sure to CMV on the reconstitution of graft cells or alterna-
tively, their level of maturation.
Evaluation of the T cell subsets demonstrated the same
response in CMV seropositive recipients, again speciﬁc to
those receiving sibling and not UCB grafts (Figure 5). For
example, at day 28 after HCT, CMV Seroþ recipients
expressed signiﬁcantly higher percentages of KIR2DL2/3þ T
cells (20%  1.6% [Seroþ/React] versus 9.5%  1.6% [Sero/
React]; P< .0001) (Figure 5A). The NKG2A-expressing Tcells
were decreased (19%  2.1% [Seroþ/React] versus
29% 2.6% [Sero/React]; P¼ .003) by 6 months (Figure 5B)
and we observed increased T cells bearing the adaptive
phenotypes NKG2CþCD57þ (8.5%  2.3% [Seroþ/React]
versus 3.3%  1.1% [Sero/React]; P ¼ .04] and
NKG2CþCD57 (4.2%  1.0% [Seroþ/React] versus 1.5%  .4%
[Sero/React]; P ¼ .01) (Figure 5C,D). Recipient CMV seros-
tatus was not associated with any changes in T lymphocyte
reconstitution in the recipients of UCB grafts (Figure 5E-H).
CMV Reactivation is Reduced in Recipients of Allogeneic
Sibling versus UCB Grafts
We evaluated the incidence of CMV reactivation in a
larger cohort of 394 CMV Seroþ recipients of sibling (n¼ 124)
and UCB (n¼ 270) grafts (see demographics in Supplemental
Table 1) treated at the University of Minnesota between 2001
and 2013. They all received similar CMV prophylaxis with
acyclovir and underwent routine monitoring for CMV reac-
tivation. CMV reactivation was more frequent in UCB versus
sibling HCT in adjusted univariate and regression models
(51%; 95% conﬁdence interval [CI], 45% to 57% versus 33%;
95% CI, 24% to 41%; risk ratio ¼ 1.6; 95% CI, 1.1 to 2.3; P < .01).
Figure 2. Recipient CMV Seroþ/React and Reactþ results in expansion of KIR2DL2/3þ and NKG2CþCD57þ CD56þCD3þ T cells after HCT. (A) NKG2CþCD57þ
CD56þCD3þ T cells in CMV Sero/React (black bars, n ¼ 116), Seroþ/React (light gray bars, n ¼ 53), and CMV Reactþ (white bars, n ¼ 57), (B) NKG2CþCD57, (C)
NKG2Aþ, (D) KIR2DL1þ, (E) KIR2DL2/3þ and (F) KIR3DL1þ expression was evaluated on CD56þCD3þ T cells from CMV Sero/React (black bars, n ¼ 115), Seroþ/React
(light gray bars, n ¼ 54), and CMV Reactþ (white bars, n ¼ 57). Analysis as in Figure 1. *P < .05, **P < .01, ***P < .001.
Z.B. Davis et al. / Biol Blood Marrow Transplant 21 (2015) 1653e1662 1657Although UCB units are CMV naïve, sibling donors may be
CMV Seroþ or Sero. Therefore, CMV reactivation rates of
allogeneic sibling transplant recipients were further strati-
ﬁed based on the serostatus of the stem cell donor to eval-
uate if pre-exposure of the donor to CMV antigens affected
the incidence of CMV reactivation in HCT recipients. We
found no difference in CMV reactivation between the CMV
Seroþ (n ¼ 63) and CMV Sero (n ¼ 61) donors (37% versus
33% respectively, P ¼ not signiﬁcant) indicating that donorCMV history has little or no impact on CMV reactivation in
our cohort. Analysis of the subset of patients with available
samples showed that there was no signiﬁcant difference in
adaptive lymphocytes based on adult donor CMV status
alone. Thus, CMV Seroþ recipients of UCB grafts have
signiﬁcantly higher rates of CMV reactivation compared with
recipients of sibling grafts (Figure 6). Protection from CMV
reactivation with sibling grafts was not related to the donor
CMV status, suggesting that sibling grafts contain mature NK
Figure 3. CMV Seroþ/React and Reactþ results in expansion of KIR2DL2/3þ and NKG2CþCD57þ CD56CD3þ T cells after HCT. (A) NKG2CþCD57þ T cells in Sero/
React (black bars, n ¼ 116), Seroþ/React (light gray bars, n ¼ 54), and CMV Reactþ (white bars, n ¼ 57), (B) NKG2CþCD57, (C) NKG2Aþ, (D) KIR2DL1þ, (E) KIR2DL2/
3þ, and (F) KIR3DL1þ CD56-CD3þ T cells were evaluated from Sero/React (black bars, n ¼ 116), Seroþ/React (light gray bars, n ¼ 54) and CMV Reactþ (white bars,
n ¼ 57). Analysis as in Figure 1. *P < .05, **P < .01, ***P < .001.
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adaptive NK and T cell subsets. The reconstitution of these
adaptive lymphocytes limits CMV reactivation, unlike what
was observed in UCB HCT resulting in less protection against
CMV reactivation.
DISCUSSION
We studied the NK and T cell responses to persistent/
nonreplicating or reactivated CMV after HCT. We observed
that CMV reactivation was associated with marked increasesin NK and Tcell subsets bearing the CMV adaptive phenotype
after allogeneic HCT regardless of graft source. However,
persistent/non-replicating CMV in Seroþ recipients (a lower
viral antigen exposure) induced adaptive NK cells and T cells
when patients underwent transplantation with sibling but
not UCB grafts. This adaptive change was marked by an
increased frequency of NKG2Cþ cells, with or without CD57
expression, with associated increases in KIR and decreased
NKG2A. This suggests that grafts from sibling donors are
enriched with mature NK or other accessory cells, which
Figure 4. Recipient CMV Seroþ is associated with increased KIR2DL2/3 and NKG2C expressing adaptive CD56þCD3 NK cells in React recipients of sibling but not
UCB grafts. CD56þCD3 NK cells from CMV Sero/React (:, n ¼ 77) or CMV Seroþ/React (,, n ¼ 50). Shown are the percentage of cells expressing (A) KIR2DL2/3þ,
(B) NKG2Aþ, (C) NKG2CþCD57þ or (D) NKG2CþCD57. The same subsets are shown for React UCB HCT who were either CMV Sero/React (:, n ¼ 61) or CMV Seroþ/
React (,, n ¼ 47) (E-H). Analysis as in Figures 1 through 3. *P < .05, **P < .01, ***P < .001.
Z.B. Davis et al. / Biol Blood Marrow Transplant 21 (2015) 1653e1662 1659facilitate greater and faster reconstitution of CMV-speciﬁc
NK and T cells after HCT. We demonstrated that exposure
to persistent CMV in Seroþ recipients of sibling HCT is suf-
ﬁcient to promote an adaptive NK cell and T cell response
although the magnitude of the response is greater inrecipients who reactivate CMV. We also observed reduced
rates of CMV reactivation in transplantations from sibling
donors comparedwith that after UCB grafts, regardless of the
donor CMV serostatus. Together, these ﬁndings suggest that
more mature sibling donor immune cells impart some
Figure 5. Recipient CMV seroþ is associated with increased KIR2DL2/3 and NKG2C expressing adaptive CD56þCD3þ T cells in React recipients of sibling but not UCB
grafts. CD56þCD3þ T cells CMV Sero/React (:, n ¼ 73) or CMV Seroþ/React (,, n ¼ 106). Shown are the percentage of cells expressing (A) KIR2DL2/3þ, (B)
NKG2Aþ, (C) NKG2CþCD57þ, or (D) NKG2CþCD57. The same subsets are shown for React UCB HCT who were either CMV Sero/React (:, n ¼ 59) or CMV Seroþ/
React (,, n ¼ 47) (E-H). Analysis as in Figures 1 through 3 *P < .05, **P < .01, ***P < .001.
Z.B. Davis et al. / Biol Blood Marrow Transplant 21 (2015) 1653e16621660protection against reactivation of CMV in Seroþ recipients,
even when the sibling donors are CMV naïve.
We also demonstrated that the adaptive response to NK
and T cell subsets is CMV speciﬁc, as there is no increase in
NKG2CþCD57þ cells in CMV Sero recipients who do not
reactivate CMV. However, both persistent/nonreplicatingand reactivated CMV lead to NK cell maturation evidenced by
less frequent NKG2A and increased KIR expression. These
ﬁndings support a model where CMV primes the immune
system based on the response to CMV-modulated HLA-E.
NKG2C and NKG2A are most often mutually exclusive, with
only rare double-positive cells. In recipients who are CMV
Figure 6. Cumulative incidence of CMV reactivation is lower in sibling versus
UCB grafts, regardless of donor serostatus. Sibling donor Seroþ, n ¼ 63; 37%
CMV reactivation; donor Sero, n ¼ 61; 33% CMV reactivation) versus UCB
grafts (n ¼ 270; 51% CMV reactivation).
Z.B. Davis et al. / Biol Blood Marrow Transplant 21 (2015) 1653e1662 1661Seroþ or who reactivate CMV, T lymphocytes undergo pro-
gramming such that their response to HLA-E transitions from
inhibition (with NKG2AþNKG2C cells) to activation (with
NKG2CþNKG2A cells). This is consistent with previous
studies demonstrating an increase of NKG2Cþ NK cells with
reduced NKG2A and increased KIRs after coculture with
CMV-infected ﬁbroblasts [18]. The same phenotype was
observed with NK cells from CMV-seropositive healthy do-
nors [17]. Our previous studies showed that NKG2CþKIRþ NK
cells that expanded after CMV reactivation were potent
producers of IFN-g after K562 target cell exposure during the
acute phase of infection and long after viral clearance [25].
Responses from NKG2CþKIRþ NK cells were also more pro-
nounced when the KIRs expressed were speciﬁc for self-HLA
[26] though not stratiﬁed for donor or recipient HLA. We
identiﬁed increases in both KIR2DL1þ and KIR2DL2/3þ pop-
ulations in CMV Seroþ patients or after CMV reactivation
[25]. The self-KIR expressing subset is critical because KIR
interaction with self-HLA promotes NK cell education and
maintains their function [27].
Exposure to CMV also led to expansions of CD56þCD3þ
and CD56CD3þ T cell subsets expressing CD57 and NKG2C.
The interplay between Tcells, NK cells, and CMV viremiamay
be important and reﬂects a polyclonal multisubset immune
response. Expansions of NKG2CþCD57þKIRþ CD56þCD3þ T
cells have been reported in individuals who have been
infected by CMV [28]. This expanded population of
KIRþCD3þCD56þ T cells is more cytotoxic than the KIR
population and is enriched for a CMV-pp65 speciﬁc TCR [28].
However, pp65-tetramer staining was not included in our
analysis and will be evaluated in future studies. It is uncer-
tain whether CD57þ or NKG2Cþ T cells mediate a direct
CMV-speciﬁc immune response, or whether they activate the
immune response through interaction with NK cells or
through secretion of cytokines.
Previous studies have reported an expansion of gd-TCRþ T
cells in individuals who reactivate CMV [29-31]. After
exposure to CMV-infected ﬁbroblasts, gdT cells show
decreased expression of the Vd2 chain and exhibit increased
IFN-g production [32]. gdT cells, as compared to abT cells, are
naturally cytotoxic [33] and are reactive against various
leukemia cell lines [32], especially when the gdTcells express
KIRs [34]. We evaluated the percentages of gdT cells 60 days
after HCT in recipients who were CMV Sero, Seroþ, or
Reactþ and found high frequencies of KIRþgdT cells in all
groups, with no differences related to CMV infection (datanot shown). Further studies are needed to determine
whether these same CMV-adaptive immune subsets mediate
other beneﬁcial effects, such as protection from malignant
relapse.
CMV Seroþ recipients of sibling donor transplants yielded
enhanced reconstitution of CMV-adaptive NK and T cell
subsets compared with recipients of UCB transplants. who
showed no response to persistent/nonreplicating recipient
CMV. Importantly, UCB-derived NK and T cells developed
into adaptive NKG2CþCD57þKIRþ subsets when recipients
reactivated CMV, a condition which presumably causes
greater density of CMV viral antigens to be presented to the
immune system. Although potent antivirals such as ganci-
clovir have reduced the dangers of CMV reactivation after
HCT and limited its mortality [35,36], we have discovered
that nonreplicating CMV in Seroþ recipients may elicit
expansion of NKG2CþCD57þ NK and T cells from sibling
donor grafts without the associated morbidity of CMV reac-
tivation. These results may have important clinical implica-
tions in light of the reports that CMV reactivation is
associatedwith a reduced risk of post-HCT relapse in patients
with acute myeloid leukemia (AML) [37,38]. It is unknown
whether these adaptive NK and/or T cells directly mediate an
anti-AML response, which needs further study. Alternatively,
it is possible that the expanded adaptive NK and T cell pop-
ulations may have increased cytokine secretion in response
to AML, thereby limiting the risk of post-HCT relapse, an area
of active investigation in our laboratory.ACKNOWLEDGMENTS
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